Online citations, reference lists, and bibliographies.
← Back to Search

Effects Of Nanosuspension Formulations On Transport, Pharmacokinetics, In Vivo Targeting And Efficacy For Poorly Water-soluble Drugs.

Y. Wang, Xiaoqing Miao, Lin Sun, J. Song, C. Bi, X. Yang, Y. Zheng
Published 2014 · Chemistry, Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
A surprisingly large proportion of new chemical entities (NCE) is emerging from the drug discovery pipeline, and many active components extracted from herbal medicines are water insoluble, which represents a great challenge for their development. Nanosuspensions, which are submicron colloidal dispersions of pure drug particles that are stabilised by a small percentage of the excipients, could dramatically enhance the saturated solubility, dissolution rate and adhesion of drug particles to cell membranes. Nanosuspensions are the most suitable for drugs that require high dosing or have limited administrative volume. After 20 years of development, several oral products and one injectable product are commercially available. The aim of this review is to fill the gap between rational formulation designs and the in vivo performance of poorly water-soluble drug nanosuspensions. Specifically, this review will correlate characteristics of nanosuspension formulations, including drug property, particle size, crystallinity, stabiliser and surface property, with their transport, pharmacokinetics, bioactivity and toxicity after delivery by different administration routes. The elucidation of the mechanisms of targeted drug delivery, cellular transport and internalisation of nanosuspensions are also reviewed to interpret the in vivo performance of these nanosuspensions. Moreover, the recent application of nanosuspensions for poorly water-soluble herbal medicines is highlighted.
This paper references
10.1016/0167-4889(93)90137-E
Coating particles with a block co-polymer (poloxamine-908) suppresses opsonization but permits the activity of dysopsonins in the serum.
S. Moghimi (1993)
10.1016/J.EJPS.2004.11.007
In vivo in vitro correlations for a poorly soluble drug, danazol, using the flow-through dissolution method with biorelevant dissolution media.
V. H. Sunesen (2005)
10.1016/j.ijpharm.2011.05.075
Preparation and antitumor study of camptothecin nanocrystals.
H. Zhang (2011)
10.1016/j.neuron.2008.01.003
The Blood-Brain Barrier in Health and Chronic Neurodegenerative Disorders
B. Zlokovic (2008)
10.3109/03639045.2011.609560
Pharmacokinetic evaluation and antitumor activity of 2-methoxyestradiol nanosuspension
S. Du (2012)
10.1016/j.ijpharm.2011.02.051
Nanosuspension for improving the bioavailability of a poorly soluble drug and screening of stabilizing agents to inhibit crystal growth.
Indrajit K. Ghosh (2011)
10.4155/fmc.11.149
Drug-permeability and transporter assays in Caco-2 and MDCK cell lines.
D. Volpe (2011)
10.1016/j.jconrel.2011.12.018
Monitoring the transport of polymeric micelles across MDCK cell monolayer and exploring related mechanisms.
Shanshan Zhao (2012)
10.1016/j.ijpharm.2011.09.041
Surface modified nevirapine nanosuspensions for viral reservoir targeting: In vitro and in vivo evaluation.
R. Shegokar (2011)
10.1016/j.colsurfb.2011.05.037
Oridonin nanosuspension enhances anti-tumor efficacy in SMMC-7721 cells and H22 tumor bearing mice.
Haiyan Lou (2011)
10.1002/jps.22446
Preparation and characterization of quercetin nanocrystals.
N. G. Sahoo (2011)
10.1016/j.jconrel.2011.12.004
Controlled pulmonary drug and gene delivery using polymeric nano-carriers.
M. Beck-Broichsitter (2012)
10.1016/j.bbalip.2012.06.001
Inhibitory effect of phospholipids on P-glycoprotein: cellular studies in Caco-2, MDCKII mdr1 and MDCKII wildtype cells and P-gp ATPase activity measurements.
S. Simon (2012)
10.1016/j.nano.2011.07.006
Effect of novel stabilizers--cationic polymers on the particle size and physical stability of poorly soluble drug nanocrystals.
W. Sun (2012)
10.1517/14656566.2012.651126
Clevidipine: a state-of-the-art antihypertensive drug under the scope
Ilse M. Espina (2012)
10.1016/j.ijpharm.2007.12.016
Studies on pharmacokinetics and tissue distribution of oridonin nanosuspensions.
L. Gao (2008)
10.3797/scipharm.1103-17
Enhanced Antihypertensive Activity of Candesartan Cilexetil Nanosuspension: Formulation, Characterization and Pharmacodynamic Study
Chetan Detroja (2011)
10.1128/AAC.45.6.1771-1779.2001
Atovaquone Nanosuspensions Show Excellent Therapeutic Effect in a New Murine Model of Reactivated Toxoplasmosis
N. Schöler (2001)
10.1007/s11671-010-9597-y
Evaluating the Suitability of Using Rat Models for Preclinical Efficacy and Side Effects with Inhaled Corticosteroids Nanosuspension Formulations
Po-Chang Chiang (2010)
10.2147/IJN.S21097
Formulation and pharmacokinetic evaluation of a paclitaxel nanosuspension for intravenous delivery
Y. Wang (2011)
10.1177/0091270003261490
The Pharmacokinetics of Nebulized Nanocrystal Budesonide Suspension in Healthy Volunteers
W. Kraft (2004)
10.1054/bjoc.2000.1260
Inhibitory effect of the reversal agents V-104, GF120918 and Pluronic L61 on MDR1 Pgp-, MRP1- and MRP2-mediated transport
R. Evers (2000)
10.1016/J.EJPB.2007.02.008
A formulation comparison, using a solution and different nanosuspensions of a poorly soluble compound.
K. Sigfridsson (2007)
10.1016/j.ejpb.2011.01.007
State of the art of nanocrystals--special features, production, nanotoxicology aspects and intracellular delivery.
R. Mueller (2011)
10.3109/03639045.2010.505927
Particle size reduction and pharmacokinetic evaluation of a poorly soluble acid and a poorly soluble base during early development
K. Sigfridsson (2011)
10.1002/jps.22112
Targeted cancer therapy with novel high drug-loading nanocrystals.
F. Liu (2010)
10.1016/J.JCONREL.2003.11.018
Drug, enzyme and peptide delivery using erythrocytes as carriers.
C. G. Millán (2004)
10.1016/j.ijpharm.2008.11.029
Development of an oral rutin nanocrystal formulation.
R. Mauludin (2009)
10.1016/J.IJPHARM.2007.02.030
Itraconazole IV nanosuspension enhances efficacy through altered pharmacokinetics in the rat.
Barrett E. Rabinow (2007)
10.1016/j.addr.2011.10.007
Nanotechnological advances for the delivery of CNS therapeutics.
H. L. Wong (2012)
10.1016/j.nano.2011.01.008
Polystyrene nanoparticle trafficking across MDCK-II.
Farnoosh Fazlollahi (2011)
10.1016/j.ijpharm.2010.10.013
Nanostructured lipid carrier (NLC) coated with Chitosan Oligosaccharides and its potential use in ocular drug delivery system.
Q. Luo (2011)
10.1016/j.ijpharm.2011.11.031
In vitro and in vivo evaluation of camptothecin nanosuspension: a novel formulation with high antitumor efficacy and low toxicity.
Liping Yao (2012)
10.1016/J.JCONREL.2006.08.013
Nanoparticles as potential oral delivery systems of proteins and vaccines: a mechanistic approach.
A. des Rieux (2006)
10.1002/jps.21372
Interactions of pluronic block copolymers on P-gp efflux activity: experience with HIV-1 protease inhibitors.
N. Shaik (2008)
10.1016/j.jconrel.2010.10.007
Hydrocortisone nanosuspensions for ophthalmic delivery: A comparative study between microfluidic nanoprecipitation and wet milling.
Hany S M Ali (2011)
10.1002/jps.22587
Nanonization of itraconazole by high pressure homogenization: stabilizer optimization and effect of particle size on oral absorption.
Wei Sun (2011)
10.1016/j.mito.2011.11.001
Functionalized nanosystems for targeted mitochondrial delivery.
S. Durazo (2012)
10.3109/02652048.2011.642015
Studies on pharmacokinetics and tissue distribution of bifendate nanosuspensions for intravenous delivery
Y. Liu (2012)
10.1016/j.brainres.2009.06.022
Neuroprotective effects of a nanocrystal formulation of sPLA2 inhibitor PX-18 in cerebral ischemia/reperfusion in gerbils
Q. Wang (2009)
10.1163/156856200744354
Insoluble ionic complexes of polyacrylic acid with a cationic drug for use as a mucoadhesive, ophthalmic drug delivery system
B. Lele (2000)
10.1080/10611860500353245
Characterization of nebulized buparvaquone nanosuspensions—effect of nebulization technology
N. Hernández-Trejo (2005)
10.1248/CPB.58.912
Physicochemical and pharmacokinetic characterization of a spray-dried cefpodoxime proxetil nanosuspension.
Y. Gao (2010)
10.1007/s11671-008-9234-1
Evaluation of Aerosol Delivery of Nanosuspension for Pre-clinical Pulmonary Drug Delivery
Po-Chang Chiang (2009)
10.1016/0163-7258(79)90119-0
Experiments on the toxic, sedative and muscle relaxant potency of various drug solvents in mice.
R. Budden (1979)
10.2174/157341307780619224
Improved Bioavailability of Albendazole Following Oral Administration of Nanosuspension in Rats
M. P. Kumar (2007)
10.1007/s10637-010-9455-x
A phase II study of 2-methoxyestradiol (2ME2) NanoCrystal® dispersion (NCD) in patients with taxane-refractory, metastatic castrate-resistant prostate cancer (CRPC)
M. Harrison (2010)
10.1016/j.ijpharm.2009.06.022
In vitro and in vivo antitumor activity of oridonin nanosuspension.
Haiyan Lou (2009)
10.1016/j.jconrel.2011.11.014
Therapeutic plasmid DNA versus siRNA delivery: common and different tasks for synthetic carriers.
Claudia Scholz (2012)
10.4314/AJB.V10I48
Evaluating the toxicity of permeability enhanchers of polyethylene glycol brij ethers surfactants group on cellular membranes and some of their physicochemical properties
G. D. Noudeh (2011)
10.1016/S0169-409X(96)00415-2
Caco-2 monolayers in experimental and theoretical predictions of drug transport
P. Artursson (1996)
10.1002/jps.21964
Formulation design and photochemical studies on nanocrystal solid dispersion of curcumin with improved oral bioavailability.
S. Onoue (2010)
10.1038/nrd1494
Nanosuspensions in drug delivery
Barrett E. Rabinow (2004)
10.1002/jcp.22788
Targeting mitochondria as a therapeutic target in cancer
C. Wenner (2012)
10.1088/0957-4484/20/22/225108
Hybrid polymeric hydrogels for ocular drug delivery: nanoparticulate systems from copolymers of acrylic acid-functionalized chitosan and N-isopropylacrylamide or 2-hydroxyethyl methacrylate.
E. Barbu (2009)
10.1002/jps.21723
Investigation of the micellar effect of pluronic P85 on P-glycoprotein inhibition: cell accumulation and equilibrium dialysis studies.
N. Shaik (2009)
10.2174/138161209788923886
Nanocarriers in ocular drug delivery: an update review.
Sheetu Wadhwa (2009)
10.1016/j.jconrel.2012.03.013
Drug nanocrystals: In vivo performances.
L. Gao (2012)
10.1016/J.JNUTBIO.2005.09.002
Reversal of chemical-induced liver fibrosis in Wistar rats by puerarin.
Shuihua Zhang (2006)
10.1161/01.RES.87.11.992
Soluble Epoxide Hydrolase Regulates Hydrolysis of Vasoactive Epoxyeicosatrienoic Acids
Z. Yu (2000)
10.1016/J.JCONREL.2006.06.032
Applications of carrier erythrocytes in delivery of biopharmaceuticals.
M. Hamidi (2007)
10.1007/s11671-007-9063-7
Pharmacokinetic evaluation of a 1,3-dicyclohexylurea nanosuspension formulation to support early efficacy assessment
J. Wahlstrom (2007)
10.1016/j.ijpharm.2011.08.023
Enhanced bioavailability after oral and pulmonary administration of baicalein nanocrystal.
J. Zhang (2011)
10.1021/cn2000469
ACS chemical neuroscience molecule spotlight on ELND006: another γ-secretase inhibitor fails in the clinic.
C. Hopkins (2011)
10.1006/PHRS.2000.0763
Modulation of radiation-induced organs toxicity by cremophor-el in experimental animals.
L. Ramadan (2001)
10.1016/j.canlet.2011.03.028
In vitro antitumor activity of silybin nanosuspension in PC-3 cells.
Dandan Zheng (2011)
10.1016/j.ijpharm.2010.06.015
Self-assembled liquid crystalline nanoparticles as a novel ophthalmic delivery system for dexamethasone: Improving preocular retention and ocular bioavailability.
L. Gan (2010)
10.1166/JNN.2006.475
Design and evaluation of a self-adhesive naproxen-loaded film prepared from a nanoparticle dispersion.
A. Ganem-Quintanar (2006)
10.1016/j.ejpb.2011.09.012
Twenty years of drug nanocrystals: where are we, and where do we go?
R. Mueller (2012)
10.1002/jps.23069
Differential selectivity of efflux transporter inhibitors in Caco-2 and MDCK-MDR1 monolayers: a strategy to assess the interaction of a new chemical entity with P-gp, BCRP, and MRP2.
K. Mease (2012)
10.1007/s11095-011-0428-3
Formulation, Biological and Pharmacokinetic Studies of Sucrose Ester-Stabilized Nanosuspensions of Oleanolic Acid
Wenji Li (2011)
10.2147/IJN.S29483
Oridonin nanosuspension was more effective than free oridonin on G2/M cell cycle arrest and apoptosis in the human pancreatic cancer PANC-1 cell line
Xiaoli Qi (2012)
10.1208/s12249-010-9388-x
Dual-Drug Delivery System Based on In Situ Gel-Forming Nanosuspension of Forskolin to Enhance Antiglaucoma Efficacy
S. Gupta (2010)
10.1016/j.ejpb.2008.03.004
Permeation enhancer effect of chitosan and chitosan derivatives: comparison of formulations as soluble polymers and nanoparticulate systems on insulin absorption in Caco-2 cells.
A. Sadeghi (2008)
10.1002/jps.23034
A formulation strategy for gamma secretase inhibitor ELND006, a BCS class II compound: development of a nanosuspension formulation with improved oral bioavailability and reduced food effects in dogs.
K. Quinn (2012)
10.1016/J.IJPHARM.2006.02.045
Oral bioavailability of cyclosporine: solid lipid nanoparticles (SLN) versus drug nanocrystals.
R. Mueller (2006)
10.1007/s11095-010-0200-0
Effect of Crystal Size on the In Vitro Dissolution and Oral Absorption of Nitrendipine in Rats
Dengning Xia (2010)
10.1016/0885-4505(88)90062-X
Kinetics of propylene glycol elimination and metabolism in rat.
K. M. Morshed (1988)
10.1016/j.ijpharm.2010.09.041
Optimization of formulation and process variable of nanosuspension: An industrial perspective.
Dhananjay S. Singare (2010)
10.1208/s12249-011-9682-2
Nitrendipine Nanocrystals: Its Preparation, Characterization, and In Vitro–In Vivo Evaluation
P. Quan (2011)
10.1016/j.ijpharm.2008.07.023
Top-down production of drug nanocrystals: nanosuspension stabilization, miniaturization and transformation into solid products.
B. Van Eerdenbrugh (2008)
10.1016/J.ADDR.2007.08.029
Cell-based drug delivery.
F. Pierigé (2008)
10.1016/S0016-5085(89)80072-1
Characterization of the human colon carcinoma cell line (Caco-2) as a model system for intestinal epithelial permeability.
I. Hidalgo (1989)
10.2174/138161206778194024
Hypersensitivity reactions to ophthalmic products.
M. T. Ventura (2006)
Resveratrol nanosuspensions for dermal application--production, characterization, and physical stability.
S. Kobierski (2009)
10.1021/MP060121R
Mechanism of inhibition of P-glycoprotein mediated efflux by vitamin E TPGS: influence on ATPase activity and membrane fluidity.
E. Collnot (2007)
10.1016/j.ijpharm.2012.04.025
A novel surface modified nitrendipine nanocrystals with enhancement of bioavailability and stability.
P. Quan (2012)
10.1016/J.EJPB.2007.01.007
Dexamethasone-loaded nanoparticle-coated microparticles: correlation between in vitro drug release and drug transport across Caco-2 cell monolayers.
R. Beck (2007)
10.1016/S0928-0987(02)00057-X
Eudragit RS100 nanosuspensions for the ophthalmic controlled delivery of ibuprofen.
R. Pignatello (2002)
10.1016/j.nano.2010.10.012
In vitro protein adsorption studies on nevirapine nanosuspensions for HIV/AIDS chemotherapy.
R. Shegokar (2011)
10.1088/0957-4484/21/15/155104
In vitro and in vivo evaluation of silybin nanosuspensions for oral and intravenous delivery.
Y. Wang (2010)
10.1016/j.chroma.2011.08.033
A sensitive analysis method for 7 diterpenoids in rat plasma by liquid chromatography-electrospray ionization mass spectrometry and its application to pharmacokinetic study of Isodon serra extract.
Yingfeng Du (2011)
10.1016/J.JCONREL.2007.02.014
Phosphatidylcholine embedded microemulsions: physical properties and improved Caco-2 cell permeability.
Aviram Spernath (2007)
10.1002/jps.21380
Fluticasone and budesonide nanosuspensions for pulmonary delivery: preparation, characterization, and pharmacokinetic studies.
J. Z. Yang (2008)
10.1602/neurorx.2.1.3
The blood-brain barrier: Bottleneck in brain drug development
W. Pardridge (2011)
10.1016/j.ijpharm.2011.04.031
Chitosan/sulfobutylether-β-cyclodextrin nanoparticles as a potential approach for ocular drug delivery.
Azza A. Mahmoud (2011)
10.1166/JNN.2012.6436
Formulation and pharmacokinetics evaluation of puerarin nanocrystals for intravenous delivery.
Y. Wang (2012)
10.1016/S1773-2247(12)50031-6
Novel multifunctional cyclodextrin-based nanocarriers for drug encapsulation and delivery as a strategy to overcome current therapeutic drawbacks
K. Yannakopoulou (2012)
10.1002/jps.22440
Usefulness of a nanoparticle formulation to investigate some hemodynamic parameters of a poorly soluble compound.
K. Sigfridsson (2011)
10.1016/j.ejps.2010.05.002
Intestinal permeability enhancement of levothyroxine sodium by straight chain fatty acids studied in MDCK epithelial cell line.
Dimple Pabla (2010)
10.1021/mp900191s
Vitamin E TPGS P-glycoprotein inhibition mechanism: influence on conformational flexibility, intracellular ATP levels, and role of time and site of access.
E. Collnot (2010)
10.1158/1078-0432.CCR-08-1599
Phase I Trial of 2-Methoxyestradiol NanoCrystal Dispersion in Advanced Solid Malignancies
A. Tevaarwerk (2009)
10.3109/03639041003695139
Preparation, characterization, pharmacokinetics, and tissue distribution of curcumin nanosuspension with TPGS as stabilizer
Y. Gao (2010)
10.1128/AAC.01529-09
Pharmacokinetics and Disposition of Rilpivirine (TMC278) Nanosuspension as a Long-Acting Injectable Antiretroviral Formulation
Gerben van 't Klooster (2010)
10.1016/J.IJPHARM.2007.02.005
Characterization of physico-chemical properties and pharmaceutical performance of sucrose co-freeze-dried solid nanoparticulate powders of the anti-HIV agent loviride prepared by media milling.
B. Van Eerdenbrugh (2007)
10.1186/1556-276X-6-413
Investigation of utilization of nanosuspension formulation to enhance exposure of 1,3-dicyclohexylurea in rats: Preparation for PK/PD study via subcutaneous route of nanosuspension drug delivery
Po-Chang Chiang (2011)
10.1016/j.clinthera.2012.07.004
Bioavailability and tolerability of combination treatment with revaprazan 200 mg + itopride 150 mg: a randomized crossover study in healthy male Korean volunteers.
H. Y. Choi (2012)
10.1166/JBN.2012.1444
In vivo evaluation of silybin nanosuspensions targeting liver.
Y. Wang (2012)
10.1016/S0378-5173(02)00040-6
Buparvaquone mucoadhesive nanosuspension: preparation, optimisation and long-term stability.
R. Mueller (2002)
10.1016/j.ejps.2010.12.005
Influence of polyunsaturated fatty acids on Cortisol transport through MDCK and MDCK-MDR1 cells as blood-brain barrier in vitro model.
C. Navarro (2011)
10.1007/s11095-006-9132-0
Micellar Nanocarriers: Pharmaceutical Perspectives
V. Torchilin (2006)
10.1016/j.ijpharm.2009.09.030
Fabrication of drug nanoparticles by evaporative precipitation of nanosuspension.
M. Kakran (2010)
Nevirapine nanosuspensions for HIV reservoir targeting.
R. Shegokar (2011)
10.1021/bm201270m
Galactose-decorated pH-responsive nanogels for hepatoma-targeted delivery of oridonin.
Cunxian Duan (2011)
10.1211/0022357023691
Nanosuspensions: a promising drug delivery strategy
V. Patravale (2004)
10.1016/j.ejps.2010.04.006
Preparation of stable nitrendipine nanosuspensions using the precipitation-ultrasonication method for enhancement of dissolution and oral bioavailability.
Dengning Xia (2010)
10.1016/J.BIOMATERIALS.2006.11.028
Ocular drug delivery by liposome-chitosan nanoparticle complexes (LCS-NP).
Y. Diebold (2007)
10.1081/DDC-52182
Nanosuspension Formulations for Low-Soluble Drugs: Pharmacokinetic Evaluation Using Spironolactone as Model Compound
P. Langguth (2005)
10.1111/j.1742-7843.2008.00213.x
Oral delivery of 1,3-dicyclohexylurea nanosuspension enhances exposure and lowers blood pressure in hypertensive rats.
S. Ghosh (2008)
10.1016/j.jconrel.2009.09.026
Differential metabolic responses to pluronic in MDR and non-MDR cells: a novel pathway for chemosensitization of drug resistant cancers.
Daria Y. Alakhova (2010)
10.1016/S0928-0987(02)00251-8
Nanosizing: a formulation approach for poorly-water-soluble compounds.
E. Merisko-Liversidge (2003)
10.1128/AEM.00193-12
Impacts of Hematite Nanoparticle Exposure on Biomechanical, Adhesive, and Surface Electrical Properties of Escherichia coli Cells
W. Zhang (2012)
10.1007/BF03190199
Cell culture techniques for the study of drug transport
G. Wilson (2010)
10.1023/A:1014276917363
Production and Characterization of a Budesonide Nanosuspension for Pulmonary Administration
C. Jacobs (2004)
10.1016/j.ijpharm.2008.12.030
Production and characterization of Hesperetin nanosuspensions for dermal delivery.
P. R. Mishra (2009)
10.1016/0378-5173(95)00122-Y
Particle size reduction for improvement of oral bioavailability of hydrophobic drugs: I. Absolute oral bioavailability of nanocrystalline danazol in beagle dogs
G. Liversidge (1995)
Preserving hesperetin nanosuspensions for dermal application.
L. Al Shaal (2010)
10.1517/17425247.2011.542142
Ocular drug delivery – a look towards nanobioadhesives
L. D. du Toit (2011)
10.1080/17458080601134540
1,3-Dicyclohexyl urea nanosuspension for intravenous steady-state delivery in rats
Po-Chang Chiang (2007)
10.1016/j.ijpharm.2011.01.032
Evaluation of a crystalline nanosuspension: polymorphism, process induced transformation and in vivo studies.
P. Sharma (2011)
10.1016/j.ijpharm.2010.07.044
Nanocrystals: industrially feasible multifunctional formulation technology for poorly soluble actives.
R. Shegokar (2010)
10.1002/jps.21479
Reversal of multidrug resistance by methoxypolyethylene glycol-block-polycaprolactone diblock copolymers through the inhibition of P-glycoprotein function.
Praveen Elamanchili (2009)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar